These data further confirmed that PRAP1 upregulation increased the interaction between MAD1 and MAD2 and competitively inhibited the binding of BUBR1 to MAD2 in vivo, resulting in MCC formation disorder and the formation of cisplatin-resistant tumors. The gene discussed is PRAP1; the disease is Merkel cell skin cancer.